Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,332 | -19,913 | 5,696 | 21,031 | 12,827 |
| Depreciation Amortization | 1,451 | 781 | 4,133 | 3,179 | 2,135 |
| Accounts receivable | -24,757 | 284 | 1,551 | 1,291 | 1,186 |
| Accounts payable and accrued liabilities | -496 | 656 | -2,397 | -2,402 | -1,887 |
| Other Working Capital | -38,527 | -1,249 | -27,780 | -22,258 | -10,609 |
| Other Operating Activity | 38,907 | 3,081 | 19,914 | 14,986 | 9,969 |
| Operating Cash Flow | $-38,754 | $-16,360 | $1,117 | $15,827 | $13,621 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 14 | N/A | -42 | -223 | -215 |
| Investing Cash Flow | $14 | $N/A | $-42 | $-223 | $-215 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,143 | 428 | 13,898 | 1,241 | 1,180 |
| Financing Cash Flow | $2,143 | $428 | $13,898 | $1,241 | $1,180 |
| Beginning Cash Position | 54,434 | 54,434 | 39,461 | 39,461 | 39,461 |
| End Cash Position | 17,837 | 38,502 | 54,434 | 56,306 | 54,047 |
| Net Cash Flow | $-36,597 | $-15,932 | $14,973 | $16,845 | $14,586 |
| Free Cash Flow | |||||
| Operating Cash Flow | -38,754 | -16,360 | 1,117 | 15,827 | 13,621 |
| Capital Expenditure | N/A | N/A | -252 | -223 | -215 |
| Free Cash Flow | -38,754 | -16,360 | 865 | 15,604 | 13,406 |